Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent ... Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which has completed Phase III clinical studies to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is headquartered in Stockholm, Sweden. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 6.18 | 6.18 | 6.18 | 0 | 0 | CS |
| 26 | 0.71 | 12.9798903108 | 5.47 | 6.18 | 5.47 | 169 | 5.73257396 | CS |
| 52 | -2.02 | -24.6341463415 | 8.2 | 8.2 | 4.78 | 598 | 7.60726896 | CS |
| 156 | -1.29 | -17.2690763052 | 7.47 | 8.38 | 4.78 | 506 | 7.72679978 | CS |
| 260 | -1.29 | -17.2690763052 | 7.47 | 8.38 | 4.78 | 506 | 7.72679978 | CS |
joe_techi
7分前
don estaban
8分前
barnyarddog
10分前
barnyarddog
11分前
barnyarddog
11分前
barnyarddog
12分前
EmpressRealm45
13分前
Ronnie Replay
16分前
barnyarddog
17分前
bear777
19分前
pitcook
20分前
barnyarddog
20分前
bear777
21分前
barnyarddog
23分前
avxl_going_long
25分前
Jake731
28分前
barnyarddog
32分前
bear777
32分前
barnyarddog
32分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。